Who are Anoro® Ellipta®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Indacaterol/glycopyrronium, indacaterol/glycopyrronium 110/50 Breezhaler®, Olodaterol-Tiotropium, FF/GW642444 Inhalation Powder.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anoro-ellipta.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Anoro® Ellipta® — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anoro® Ellipta® (Anoro® Ellipta®) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination). Area: Respiratory / Pulmonology.

marketed Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination) Beta-2 adrenergic receptor and M3 muscarinic acetylcholine receptor Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Anoro® Ellipta® (Anoro® Ellipta®) — AstraZeneca. Anoro Ellipta combines a long-acting beta-2 agonist and a long-acting muscarinic antagonist to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Anoro® Ellipta® TARGET	Anoro® Ellipta®	AstraZeneca	marketed	Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination)	Beta-2 adrenergic receptor and M3 muscarinic acetylcholine receptor
Indacaterol/glycopyrronium	Indacaterol/glycopyrronium	Orion Corporation, Orion Pharma	marketed	Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination)	Beta-2 adrenergic receptor; M3 muscarinic acetylcholine receptor
indacaterol/glycopyrronium 110/50 Breezhaler®	indacaterol/glycopyrronium 110/50 Breezhaler®	Wouter H. van Geffen	marketed	Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination)	Beta-2 adrenergic receptor; Muscarinic M3 acetylcholine receptor
Olodaterol-Tiotropium	Olodaterol-Tiotropium	Fraunhofer-Institute of Toxicology and Experimental Medicine	marketed	Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination)	Beta-2 adrenergic receptor; M3 muscarinic receptor
FF/GW642444 Inhalation Powder	FF/GW642444 Inhalation Powder	GlaxoSmithKline	phase 3	Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination)	Beta-2 adrenergic receptor; M3 muscarinic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination) class)

AstraZeneca · 1 drug in this class
Fraunhofer-Institute of Toxicology and Experimental Medicine · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Orion Corporation, Orion Pharma · 1 drug in this class
Wouter H. van Geffen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anoro® Ellipta® — Competitive Intelligence Brief. https://druglandscape.com/ci/anoro-ellipta. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing